Drug · CHEMBL448
PENTOBARBITAL
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. PENTOBARBITAL. Drugs and targets, record CHEMBL448. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL448
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
Targets16
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
| Target | Protein | Mechanism | Action | Gene in Genes |
|---|---|---|---|---|
| GABRA1 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2554 |
| GABRA2 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2555 |
| GABRA3 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2556 |
| GABRA4 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2557 |
| GABRA5 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2558 |
| GABRA6 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2559 |
| GABRB1 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2560 |
| GABRB2 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2561 |
| GABRB3 | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2562 |
| GABRD | GABA-A receptor; anion channel | GABA-A receptor; anion channel positive allosteric modulator | POSITIVE ALLOSTERIC MODULATOR | https://conductscience.org/library/genes/2563 |
1 to 10 of 16Source ChEMBL
See all 16 targetsDiseases4
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| brain injury | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0043510 |
| intracranial hypertension | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=MONDO_0006810 |
| status epilepticus | Phase 3 | ClinicalTrials.gov | 1 | 1 | https://conductscience.org/library/drugs?q=EFO_0008526 |
| insomnia | Approval | DailyMed and TTD | 2 | 0 | https://conductscience.org/library/drugs?q=MONDO_0013600 |
Source Open Targets
Trials7
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT00265616 | Treatment of Refractory Status Epilepticus | Phase 3 | 23 | 2013-04-04 | pentobarbital | Its name | ClinicalTrials.gov |
| NCT02250820 | A Comparison of Two Sedation Techniques in Children Undergoing Transthoracic Echocardiography (TTE) | Phase 1 | 280 | pentobarbital | Its name | ClinicalTrials.gov | |
| NCT00622570 | Comparison of Effectiveness of Pentobarbital and Thiopental in Patients With Refractory Intracranial Hypertension | Phase 3 | 44 | pentobarbital | Its name | ClinicalTrials.gov | |
| NCT00058955 | Physiological, Behavioral and Subjective Effects of Drugs (GHB) | Phase 1 | 20 | pentobarbital | Its name | ClinicalTrials.gov | |
| NCT00123578 | GHB Withdrawal Symptoms and Effectiveness of Treatment With Lorazepam Versus Pentobarbital - 1 | Phase 1/2 | 0 | pentobarbital | Its name | ClinicalTrials.gov | |
| NCT00878345 | Dexmedetomidine Versus Pentobarbital for Pediatric Procedural Sedation | 0 | pentobarbital | Its name | ClinicalTrials.gov | ||
| NCT04350528 | Comparison of Chlorpromazine or Pentobarbital Premedications for Pediatric Imaging Procedures | 254 | pentobarbital | Its name | ClinicalTrials.gov |
Comparisons in its trials6
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Propofol vs Thiopental/Pentobarbital: Refractory Status Epilepticus Controlled With First Course of Study Drug | 6 of 14 | 2 of 9 | 23 | NCT00265616 | Trial comparisons |
| Propofol vs Thiopental/Pentobarbital: Patients With Hypotension Requiring Specific Treatment | 7 of 14 | 5 of 9 | 23 | NCT00265616 | Trial comparisons |
| Propofol vs Thiopental/Pentobarbital: Patients With Propofol Infusion Syndrome | 1 of 14 | 0 of 9 | 23 | NCT00265616 | Trial comparisons |
| Propofol vs Thiopental/Pentobarbital: Patients With Infectious Complications Requiring Specific Treatment | 7 of 14 | 6 of 9 | 23 | NCT00265616 | Trial comparisons |
| Propofol vs Thiopental/Pentobarbital: Clinical Outcome at Day 21 | 5 of 14 | 3 of 9 | 23 | NCT00265616 | Trial comparisons |
| Propofol vs Thiopental/Pentobarbital: serious adverse events | 1 of 14 | 1 of 9 | 23 | NCT00265616 | Trial comparisons |
Papers from its trials4
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Tests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL448
GET https://conductscience.org/api/drugs/v1/CHEMBL448/targets